News | November 06, 2024
Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Strokes are affecting approximately 1.8 million people annually
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
CSPC will receive an upfront payment of $100 million from AstraZeneca
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Subscribe To Our Newsletter & Stay Updated
